TransMedics' (NASDAQ: TMDX ) stock has rebounded somewhat in recent months, which has been supported by stronger transplant volumes and easing concerns about competition. Despite this, TransMedics' share price remains low given the company's guidance. While I think that TransMedics' longer-term targets could be overly aggressive, growth isRichard Durant is the leader of Narweena, an asset manager focused on finding market dislocations that are the result of a poor understanding of a businesses long-term pro ...